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Objective: Aortomyoplasty is an experimental surgical procedure in which the
latissimus dorsi muscle is wrapped around the thoracic aorta and stimulated to
contract during diastole, providing diastolic counterpulsation. We hypothesized that
aortomyoplasty could improve cardiac function in a chronic ischemic heart failure
model, similar to the improvement seen with the intra-aortic balloon pump.
Methods: Six dogs (25-30 kg) successfully underwent aortomyoplasty followed by
serial coronary microembolization. Ejection fraction decreased from 63.5% to
36.5%. Two weeks after the final microembolization, the muscle was conditioned
for 4 months to achieve fatigue resistance. One year after aortomyoplasty, hemo-
dynamic studies during 1 hour of aortomyoplasty and 1 hour of intra-aortic balloon
counterpulsation determined mean diastolic aortic pressure, peak left ventricular
pressure, and endocardial viability ratio for assisted and unassisted beats. Cardiac
output, stroke volume, and parameters of cardiac function were also measured.
Results: Endocardial viability ratio increased by 23.8%  7.9% (P  .001) with
aortomyoplasty counterpulsation and by 22.7%  12.9% (P  .021) with the
intra-aortic balloon pump. Both aortomyoplasty and the intra-aortic balloon pump
significantly increased mean diastolic aortic pressure and reduced peak left ventric-
ular pressure. Improvements in cardiac function with aortomyoplasty and the
intra-aortic balloon pump were similar. Cardiac output increased from 2.61  0.88
to 3.07  1.06 L/min (P  .006), and index of afterload decreased from 5.4  1.4 to
4.8  1.4 mm Hg/mL (P  .02) during 1 hour of aortomyoplasty counterpulsation.
Conclusion: One year after the procedure, aortomyoplasty counterpulsation pro-
vided diastolic augmentation and improved cardiac performance similar to the
improvement provided by the intra-aortic balloon pump in a chronic ischemic heart
failure model. Aortomyoplasty has the potential to benefit patients with ischemic
heart disease refractory to current therapies.
Ischemic heart disease affects 26,000,000 Americans.1 Angioplasty andcoronary artery bypass grafting have been the mainstay therapies, with 1.48million procedures performed in 1998.1 Each year approximately 100,000patients who are not candidates for revascularization continue to experienceischemic symptoms despite maximal medical therapy.2 As a result, therehas been a growing interest in alternative therapies and assist devices for
patients with ischemic heart failure who cannot be helped by pharmacologic
treatment, are not candidates for revascularization, or are awaiting a heart transplant.
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Ischemia caused by compromised perfusion leads to
myocardial hibernation, a state of left ventricular contractile
dysfunction that is often reversed by revascularization and
an improvement in myocardial oxygen supply.3,4 Diastolic
counterpulsation can improve myocardial oxygen supply by
increasing coronary perfusion and can decrease myocardial
oxygen demand by reducing afterload. The most common
form of diastolic counterpulsation is the intra-aortic balloon
pump (IABP). The IABP continues to be beneficial for
complications of myocardial infarction, end-stage cardio-
myopathy, and postcardiotomy cardiogenic shock.5-7 Re-
fractory unstable angina has also been treated with the
IABP5-7 and the enhanced external counterpulsation device,
which uses external compression of the lower extremities to
augment diastole.8
An experimental surgical procedure that generates autol-
ogous diastolic counterpulsation is aortomyoplasty, in
which the latissimus dorsi muscle (LDM) is wrapped
around the ascending or descending thoracic aorta and stim-
ulated to contract during diastole. Aortomyoplasty can in-
crease coronary blood flow through diastolic augmenta-
tion9-11 and can decrease left ventricular work through
afterload reduction.12 Although the application of skeletal
muscle extra-aortic counterpulsation is not a new idea and
has had limited success clinically, indications for its use
have been diverse.13,14 We propose that the enhanced cor-
onary perfusion of chronic aortomyoplasty counterpulsation
may benefit patients with ischemic heart disease who have
exhausted pharmacologic options and are not candidates for
revascularization.
Previous work in our laboratory involved optimizing
aortomyoplasty muscle stimulation to cardiac cycle timing,
showing an increase in coronary blood flow with aortomyo-
plasty counterpulsation, optimizing muscle wrap configura-
tion to yield the greatest hemodynamic benefits, and dem-
onstrating the integrity of the LDM 6 months after
aortomyoplasty.9,15-17 The purpose of this investigation was
to confirm the long-term stability of the aortomyoplasty
muscle wrap and to evaluate the efficacy of acute aorto-
myoplasty counterpulsation in comparison with the IABP in
a chronic ischemic heart failure model. We hypothesized
that 1 year after the procedure, aortomyoplasty counterpul-
sation would provide cardiac benefits equivalent to the
IABP in a chronically ischemic heart.
Material and Methods
Six male mongrel dogs (25-30 kg) completed the study. The
procedures were performed in compliance with the “Principles of
Laboratory Animal Care” of the National Society for Medical
Research and the “Guide for the Care and Use of Laboratory
Animals” prepared by the Institute of Laboratory Animal Re-
sources, National Research Council, and published by the National
Academy Press, revised 1996. The Case Western Reserve Univer-
sity Institutional Animal Care and Usage Committee also approved
the protocol.
Descending Aortomyoplasty
Ten mongrel dogs underwent aortomyoplasty. General anesthesia
was induced with buprenorphine (0.3 mg subcutaneously) and
sodium thiopental (25 mg/kg intravenously). After endotracheal
intubation, anesthesia was maintained with isoflurane (1%-2%).
Prophylactic cefazolin (1 g) and fluids were administered intrave-
nously. The animal was monitored by continuous electrocardiog-
raphy (ECG) and pulse oximetry. In the left thoracotomy position,
an axillary incision extending to midthorax was made for the left
LDM to be mobilized. The neurovascular bundle was preserved,
and intramuscular pacing electrodes were implanted near the tho-
racodorsal nerve. The electrodes were tunneled subcutaneously to
exit between the scapulae, where they were later attached to a
portable stimulator. Through a left fifth interspace thoracotomy,
the descending thoracic aorta was exposed, and several intercostal
arteries were ligated as needed to allow the muscle to be wrapped
around the aorta. After resection of a 4-cm portion of the second
rib, the LDM was transposed into the chest. With the “wringer
wrap” configuration developed in our laboratory (Figure 1), the
LDM was divided longitudinally, with the oblique-transverse por-
tion wrapped clockwise around the proximal part of the descend-
ing thoracic aorta and the lateral portion of the muscle wrapped
counterclockwise distally.15 The muscle was then secured to itself.
Microembolization
Several months after aortomyoplasty, serial coronary microembo-
lizations were performed. General anesthesia was induced with
diazepam (0.165 mg/kg intravenously), pentobarbital (10 mg/kg
intravenously), and hydromorphone (0.29 mg/kg intravenously).
After endotracheal intubation, prophylactic cefazolin (1 g) and
fluids were administered intravenously. Animals were monitored
throughout the procedure with a continuous ECG and pulse oxim-
etry. After isolation of the femoral artery to catheterize the left
heart, heparin (1500 units intravenously) was administered. A
Judkins preformed coronary catheter (JL-4) was positioned in the
left anterior descending or circumflex coronary artery under fluo-
Figure 1. Aortomyoplasty wringer wrap configuration: LDM
wrapped around descending thoracic aorta.
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roscopic guidance. Subsequently, a mixture consisting of 0.5-mL
Polybead (Polysciences Inc, Warrington, Pa) polystyrene micro-
spheres (90 m in diameter, approximately 40,000 particles/[mL 
injection]) with 0.5-mL radiographic contrast suspension
(iothalamate meglumine; Mallinckrodt Inc, St Louis, Mo) was
delivered by bolus injection into the artery.
During each session, an average of three injections were deliv-
ered at 15-minute intervals. The ECG was monitored for ischemic
changes and arrhythmias. After embolization, propranolol (1 mg)
to minimize catecholamine surge and protamine (15 mg) to reverse
heparin were administered intravenously. The femoral artery was
then primarily repaired, and the incision was closed. Each animal
underwent approximately 9 to 14 weekly sessions of microembo-
lization. The left ventricular ejection fraction was measured with
contrast ventriculography digital analysis (Simpson method). Once
ejection fraction had decreased to approximately 35% (from base-
line of 63.5%  6.0% to 36.5%  3.6%, P  .05), the microem-
bolization sessions were discontinued. Six dogs survived the mi-
croembolization procedures.
Muscle Conditioning
Two weeks after the final microembolization, long-term muscle
conditioning was initiated and was continued for approximately 4
months. A fitted jacket securing a portable stimulator was attached
to the muscle pacing electrodes that exited between the scapulae.
The stimulator was programmed to supply a pulse frequency of 2
Hz (24 h/d) with an amplitude of 3 to 4 V and a pulse width of 210
s, sufficient to twitch the LDM.18 The twitch was detected by
palpation of the left axillary region. The 2-Hz frequency protocol
is well documented for developing a fatigue-resistant LDM by
converting the type II (fast twitch) muscle fibers to type I (slow
twitch) muscle fibers.19,20
Hemodynamic Studies
Four months after the final microembolization session (1 year after
aortomyoplasty), peak left ventricular pressure, mean diastolic
aortic pressure, and endocardial viability ratio were measured for
assisted and unassisted beats during 1 hour of aortomyoplasty and
1 hour of IABP counterpulsation. Endocardial viability ratio is the
ratio of the diastolic pressure time index to systolic tension-time
index, which correlates to the myocardial oxygen supply-to-
demand ratio and is an index of the extent of counterpulsation.21
General anesthesia was induced as for the aortomyoplasty
surgery. A 7.5F Swan-Ganz catheter (Baxter Healthcare Corp,
Edwards Division, Santa Ana, Calif) was positioned to measure
pressures, cardiac output (CO), and stroke volume. Under fluoro-
scopic guidance, a combination pressure and conductance catheter
(Millar Instruments, Inc, Houston, Tex) was advanced through the
carotid artery into the left ventricle. The conductance catheter was
attached to a signal conditioner and processor for calculation of an
uncalibrated volume signal (Leycom Sigma 5; Cardiodynamics,
Zoetermeer, The Netherlands). Stroke volume and ejection frac-
tion were used to calibrate the volume signal. Analog signals were
continuously monitored (Gould Electronics Inc, Eastlake, Ohio)
and were recorded digitally by computer during a respiratory
pause.
The left ventricular pressure and volume data were used to plot
pressure-volume loops during 1:2 aortomyoplasty and 1:2 IABP
counterpulsation. For each sampling of the waveforms, the cardiac
cycles were separated into assisted and unassisted beats to com-
pare the extent of augmentation. The following indices were de-
rived from the pressure-volume loops: maximal elastance (Emax),
the slope of the end-systolic pressure and volume relationship or
the index of contractility; effective arterial elastance (Ea), the ratio
of the end-systolic pressure to stroke volume or the index of
afterload; preload recruitable stroke work (PRSW), the ratio of
stroke work to end-diastolic volume; and the ventriculoarterial
(VA) coupling index (Ea/Emax), the relationship between the ven-
tricular elastance and the arterial afterload. A VA coupling index
value of 1 indicates optimal cardiac performance.
During 1 hour of aortomyoplasty counterpulsation, the LDM
was stimulated by a bench-top stimulator (AstroMed, Inc, Grass
Instrument Division, West Warwick, RI) connected to a custom-
ized computer program designed in our laboratory incorporating
Labview (National Instruments Corporation, Austin, Tex). This
software provided the timing and duration of the impulse relative
to the ECG waveform. The LDM was stimulated with a pulse
frequency of 30 Hz, amplitude of 4 to 10 V, and pulse width of 210
s duration during every other cardiac cycle, initiated at the
dicrotic notch and terminated during isovolumic contraction.
Finally, each animal underwent 1 hour of IABP counterpulsa-
tion while hemodynamic measurements were recorded. A 9.5F
IABP catheter (System 98 Pump; Datascope Corp, Montvale, NJ)
with a 25-mL balloon was introduced through the femoral artery,
and its position was confirmed under fluoroscopy. The IABP
activation was set at a 1:2 ratio, and conventional timing was
employed such that the balloon was inflated at the dicrotic notch
and deflated to yield a presystolic dip (minimal aortic pressure).
Statistical Analysis
Comparisons of the hemodynamic indices between the assisted
and unassisted beats and the cardiac function indices during un-
assisted beats at the start and the end of 1 hour of counterpulsation
were analyzed with paired t tests. All results are expressed as
mean  SD.
Results
Outcomes and Adverse Events
Ten healthy male mongrel dogs successfully underwent
aortomyoplasty without neurologic sequelae. Skin infection
at the exit site of the muscle pacing electrodes was noted in
5 animals. The infections were treated with an antibiotic
(cephalexin, 1 g orally twice daily) and local wound care.
Procainamide (500 mg) was administered intravenously to
treat arrhythmias associated with the microembolization
procedure. Each animal received a diuretic (furosemide,
10-20 mg orally twice daily) as needed for evidence of
pulmonary edema. Four dogs died of arrhythmia during the
microembolization procedures, before long-term muscle
conditioning. Six dogs successfully completed serial coro-
nary microembolization, long-term muscle conditioning,
and hemodynamic studies.
Hemodynamic Effects
One hour of counterpulsation during every other cardiac
cycle with aortomyoplasty and the IABP produced similar
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hemodynamic improvements. The myocardial oxygen supply-
to-demand ratio, endocardial viability ratio, increased by
23.8%  7.9% (P  .001) during assisted beats with
aortomyoplasty and by 22.7% 12.9% (P .021) with the
IABP (Table 1). Both aortomyoplasty and the IABP signif-
icantly increased mean diastolic aortic pressure and reduced
peak left ventricular pressure. Furthermore, the mean value
of the hemodynamic improvements at the start of the hour
did not differ significantly from the values at the end of the
hour.
Effects on Cardiac Performance
To further evaluate the efficacy of counterpulsation, the
average cardiac function indices for the unassisted beats
during the first 10 minutes of augmentation were compared
with the values during the final 10 minutes. Neither aorto-
myoplasty nor the IABP significantly changed the heart rate
throughout the hour of counterpulsation (Table 2). Although
Emax, an index of contractility, increased with both aorto-
myoplasty (2.9  1.3 to 3.1  1.4 mm Hg/mL) and the
IABP (3.2  1.6 to 3.4  1.8 mm Hg/mL), the difference
did not reach statistical significance. During aortomyoplasty
counterpulsation, Ea decreased from 5.4  1.4 to 4.8  1.4
mm Hg/mL (P  .006), indicating a reduced afterload. The
IABP also decreased Ea (5.1  2.0 to 4.8  1.6 mm
Hg/mL), but this decrease did not achieve statistical signif-
icance. PRSW increased with both methods, indicating an
increase in stroke work throughout the hour, a decrease in
end-diastolic volume throughout the hour, or both. Stroke
volume increased with aortomyoplasty (24.3  8.3 to
26.4 7.6 mL) but not with the IABP (25.2 8.3 to 25.6
8.0 mL). This in turn was reflected in a statistically signif-
icant increase in CO during aortomyoplasty, from 2.61 
0.88 to 3.07  1.06 L/min (P  .02). The VA coupling
index (Ea/Emax) decreased from 2.1  0.7 to 1.8  0.8
during aortomyoplasty and from 1.8  0.9 to 1.7  0.8
during IABP counterpulsation.
A pressure-volume analysis for the averaged unassisted
beats, comparing the start with the end of 1 hour of aorto-
myoplasty counterpulsation for a single animal, is presented
in Figure 2. The leftward shift of the pressure-volume loop
from the start to the end of the hour represents improved
cardiac performance, with an increase in Emax (contractility)
and a decrease in Ea (afterload). Figure 3 represents the
trends in the indices of cardiac function during aortomyo-
plasty counterpulsation. The values are percentage changes
relative to the baseline. With the onset of counterpulsation,
there were gradual increases in stroke volume, CO, Emax,
and PRSW and a decrease in Ea as the hour progressed.
When the LDM stimulation was turned off, all values ap-
proached baseline.
Discussion
The IABP benefitted 155,000 patients globally in 1999
(Datascope Corp, personal communication). As the criterion
standard of diastolic counterpulsation, the IABP has as-
sisted patients with cardiogenic shock, unstable angina, and
myocardial infarction; however, its long-term use remains
limited by such complications as thromboembolic events
and infection.5-7 Aortomyoplasty is a surgical procedure that
can provide autologous and hemocompatible counterpulsa-
tion. Because it is not limited by the complications of the
IABP, its potential to benefit the ischemic heart on a long-
term basis as an adjunct to current therapies needs to be
explored.
Successful diastolic counterpulsation enhances coronary
perfusion by diastolic augmentation and reduces left ven-
TABLE 1. Indices of hemodynamic augmentation: Aortomyoplasty counterpulsation versus the IABP in an ischemic heart
failure model
Start End
Nonaugmented Augmented
P
value % Increase Nonaugmented Augmented
P
value % Increase
Aortomyoplasty
Endocardial viability ratio 1.205 0.410 1.487 0.483 .001 23.8 7.9 1.177 0.285 1.404 0.303 .001 19.9 7.8
Mean diastolic aortic pressure
(mm Hg)
98.5 24.0 114.0 27.3 .001 15.8 3.9 96.4 23.5 108.0 26.0 .001 12.1 207
Peak left ventricular pressure
(mm Hg)
120.8 27.4 118.0 26.6 .001 2.3 0.3 120.0 26.7 116.8 25.4 .02 2.6 1.6
IABP
Endocardial viability ratio 1.234 0.162 1.526 0.358 .021 22.7 12.9 1.247 0.181 1.525 0.378 .021 21.0 11.7
Mean diastolic aortic pressure
(mm Hg)
89.2 22.9 104.5 26.9 .006 17.5 9.5 89.1 21.6 103.8 25.0 .005 16.8 8.9
Peak left ventricular pressure
(mm Hg)
112.2 25.5 109.7 24.9 .009 2.2 1.3 112.2 24.6 110.0 24.1 .004 2.0 0.9
Values are mean  SD. Start represents mean value of the first 10 minutes of augmentation; End represents mean value of the final 10 minutes of
augmentation.
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tricular work by afterload reduction.22 In this model of
ischemic heart failure, we demonstrated improved cardiac
function through sustained diastolic augmentation and af-
terload reduction during 1 hour of aortomyoplasty counter-
pulsation. Equally important was the observation that the
hemodynamic augmentation during aortomyoplasty was
comparable to that seen with the IABP.
Pressure-volume analysis of cardiac performance
showed similar improvements after 1 hour of counterpulsa-
tion with aortomyoplasty and the IABP. Although the
changes in such indices as Emax, PRSW, and CO did not
reach statistical significance, there was an overall improve-
ment in cardiac function during aortomyoplasty, as demon-
strated in Figure 3. With the onset of counterpulsation,
Emax, CO, and PRSW gradually increased, followed by a
return to baseline after the LDM stimulation was turned off.
The overall decrease in the VA coupling index during 1
hour of counterpulsation supports the contention that both
interventions were able to decrease afterload, increase ven-
tricular contractility, or both. We speculate that the small
number of animals in the study (n  6) and the moderate
degree of ischemic damage could explain why certain val-
ues of cardiac performance did not reach statistical signif-
icance. Furthermore, a longer period of diastolic augmen-
tation may be necessary for complete recovery of cardiac
function.
Although heart failure models such as rapid ventricular
pacing and propranolol administration have been used to
demonstrate the effects of aortomyoplasty counterpulsa-
tion,12,19,21 we chose the sequential coronary microemboli-
zation model for several reasons. Coronary microemboliza-
tion leads to reduced ejection fraction, increased left
TABLE 2. Indices of cardiac performance: Aortomyoplasty counterpulsation versus the IABP in an ischemic heart failure
model
Aortomyoplasty IABP
Start End P value Start End P value
Heart rate (beats/min) 114.7 22.7 117.5 25.9 .429 111.3 23.3 114.0 22.4 .323
Emax (mm Hg/mL) 2.9 1.3 3.1 1.4 .610 3.2 1.6 3.4 1.8 .393
Ea (mm Hg/mL) 5.4 1.4 4.8 1.4 .006 5.1 2.0 4.8 1.6 .431
Ea/Emax 2.1 0.7 1.8 0.8 .262 1.8 0.9 1.7 0.8 .140
PRSW (mm Hg) 38.1 15.9 41.6 16.6 .357 39.7 18.4 41.4 18.8 .068
Stroke volume (mL) 24.3 8.3 26.4 7.6 .134 25.2 8.3 25.6 8.0 .751
CO (L/min) 2.61 0.88 3.07 1.06 .020 2.81 0.74 2.86 0.95 .813
Values are mean of unassisted beats  SD. Start represents mean value of the first 10 minutes of augmentation; End represents mean value of the final
10 minutes of augmentation.
Figure 2. Pressure-volume analysis during aortomyoplasty counterpulsation. Averaged unassisted pressure-volume
loop of single animal at start (solid line) and end (dashed line) of 1 hour of aortomyoplasty counterpulsation. P,
Pressure in millimeters of mercury; V, volume in milliliters.
Hedayati et al Cardiopulmonary Support and Physiology
The Journal of Thoracic and Cardiovascular Surgery ● Volume 123, Number 6 1071
CS
P
ventricular end-diastolic pressure, and elevated plasma nor-
epinephrine levels.23,24 The chronic changes of this model
support the argument that multiple embolizations will ex-
haust the compensatory mechanisms of the myocardium,
leading to left ventricular dysfunction23 and compromised
coronary flow reserve.24 A model of ischemic cardiac dys-
function can benefit the most from diastolic counterpulsa-
tion. This is the first study to our knowledge to examine
aortomyoplasty in a chronic ischemic heart failure model.
Atherosclerotic plaque rupture and mural thrombus, fol-
lowed by embolization in the coronary vessels, may be
responsible for ischemic heart disease in human beings.3,25
The compromised coronary flow in response to coronary
microembolization leads to reduced myocardial contractile
function and a new steady state of perfusion-contraction
matching to preserve energy and prevent progressive is-
chemia.3,4 It has been argued that downward regulation of
energy requirement occurs with moderate myocardial is-
chemia.26 This perfusion-contraction matching has been
proposed to be a physiologic effect of the hibernating myo-
cardium.3 Myocardial function can be restored partially or
completely if the supply and demand of oxygen is favorably
changed by improving the blood supply,27,28 as occurs with
revascularization. Our results suggest that aortomyoplasty
counterpulsation may also benefit a hibernating myocar-
dium by enhancing myocardial oxygen supply and reducing
myocardial demand.
The length of our study supports the long-term potential
of aortomyoplasty. The LDM did not fatigue during the
hour of counterpulsation, which confirms the adequate con-
ditioning and the viability of the muscle 1 year after the
operation. We have previously examined muscle viability 1
year after wringer wrap aortomyoplasty, demonstrating that
biopsy samples of short-term–stimulated LDM revealed no
evidence of necrosis, fibrosis, or fatty infiltration relative to
the contralateral LDM (unpublished data). Studies involv-
ing 12 to 24 months of long-term LDM stimulation after
aortomyoplasty have also demonstrated no evidence of fibro-
sis, atrophy, or fatty infiltration of the wrapped muscle.29,30
Limitations of our study include the sole use of ejection
fraction to quantify the extent of ischemic heart damage.
Additional methods, such as the dobutamine stress test,
might better evaluate the ischemic changes after serial cor-
onary microembolization and subsequent improvement with
counterpulsation. Furthermore, cardiac benefits of aorto-
myoplasty counterpulsation were evaluated mainly by pres-
sure-volume analysis. Measurement of coronary blood flow
and myocardial oxygen consumption could further demon-
strate the benefits of counterpulsation.
In summary, aortomyoplasty can provide hemodynamic
augmentation comparable to that of the IABP, but without
the attendant complications.9,11,12 We have demonstrated
that acute aortomyoplasty counterpulsation improves car-
diac function in a chronic ischemic heart failure model.
Future studies should establish the ability of aortomyoplasty
to provide long-term counterpulsation capable of attenuat-
ing the symptoms of ischemic heart disease. Evidence that
long-term counterpulsation by means such as enhanced
external counterpulsation devices can benefit patients with
angina8 supports the potential of long-term counterpulsation
devices in the clinical setting. For patients with ischemic
heart disease that is refractory to current therapies, aorto-
myoplasty may provide long-term relief through diastolic
augmentation and systolic unloading.
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Discussion
Dr George L. Hicks, Jr (Rochester, NY). This was an elegant
long-term study. Clearly, in a chronically ischemic model you
need to increase diastolic flow while you are treating heart failure
by decreasing cardiac work. So what were your results in terms of
the left ventricular dynamics?
Dr Hedayati. Although the data were not presented, we did
measure load-independent and load-dependent variables of cardiac
performance with a conductance catheter that measured ventricular
volume. Values such as contractility, stroke work, preload re-
cruitable stroke work, and afterload did improve during counter-
pulsation, with some of the values reaching statistical significance.
These are discussed at length in our manuscript.
Dr Ernst Wolner (Vienna, Austria). I have two comments.
Number one, usually patients who use such a device have a
calcified and inflexible aorta. That is why we use fresh homografts
and a large pericardial patch to obtain similar results.
Number two, in the early 1970s, as balloon pumping came up,
I had used at that time (before the transplant era) in some patients
so-called long-term balloon pumping in cardiomyopathy, where
we implanted the balloon pump over the iliac artery and had it
tunneled under the skin. The long-term effect of this treatment at
that time was more or less inefficient, so I have some concern that
you can assist patients with cardiomyopathy with such a device.
However, it is an elegant study.
Dr Hedayati. Aortic calcification is a contraindication to aor-
tomyoplasty. With respect to your second comment, our study was
based on an ischemic heart failure model in which we compared
aortomyoplasty with the IABP, which has been the criterion stan-
dard of diastolic counterpulsation. Currently, diastolic augmenta-
tion is achieved with lower extremity external compression de-
vices in patients with unstable angina, and this has been effective
long-term in clinical practice.
Dr Paul Kurlansky (Miami Beach, Fla). I congratulate you on
an interesting study. I note that from the enhanced external coun-
terpulsation literature we find that 35 weeks of treatment with
external counterpulsation can result in increased myocardial per-
fusion and actually symptomatic benefit that will last 3 years after
therapy has stopped. I was just wondering whether you have any
long-term experiments which show changes in myocardial perfusion.
Dr Hedayati. The aortomyoplasty procedure and subsequent
muscle stimulation and conditioning were performed during the
year before the acute studies. Our long-term plans would be to
show the effects of chronic aortomyoplasty counterpulsation and
to examine the effects on the myocardium with tests such as stress
echocardiography.
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